Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack.

The Cochrane Database of Systematic Reviews
Thomas P ZonneveldNyika D Kruyt

Abstract

Stroke is an important cause of death and disability worldwide. Since high blood pressure is an important risk factor for stroke and stroke recurrence, drugs that lower blood pressure might play an important role in secondary stroke prevention. To investigate whether blood pressure-lowering drugs (BPLDs) started at least 48 hours after the index event are effective for the prevention of recurrent stroke, major vascular events, and dementia in people with stroke or transient ischaemic attack (TIA). Secondary objectives were to identify subgroups of people in which BPLDs are effective, and to investigate the optimum systolic blood pressure target after stroke or TIA for preventing recurrent stroke, major vascular events, and dementia. In August 2017, we searched the Trials Registers of the Cochrane Stroke Group and the Cochrane Hypertension Group, the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), MEDLINE Ovid (1946 to August 2017), Embase Ovid (1974 to August 2017), ClinicalTrials.gov, the ISRCTN Registry, Stroke Trials Registry, Trials Central, and the World Health Organization (WHO) International Clinical Trials Registry Platform Portal. Randomised controlled trials (RCTs) of BPLDs started at least 48...Continue Reading

References

Oct 31, 1991·The New England Journal of Medicine·UNKNOWN Dutch TIA Trial Study GroupAnet van Latum
Mar 7, 1970·Lancet·A B Carter
Jul 22, 1974·JAMA : the Journal of the American Medical Association
Dec 1, 1993·Stroke; a Journal of Cerebral Circulation·K IrieT Omae
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jun 21, 2003·Stroke; a Journal of Cerebral Circulation·Joachim SchraderUNKNOWN Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Dec 13, 2003·Stroke; a Journal of Cerebral Circulation·N ChapmanUNKNOWN Writing Committee for the PROGRESS Collaborative Group
Apr 13, 2004·Journal of Hypertension·Anthony RodgersUNKNOWN Perindopril Protection against Recurrent Stroke Study Collaborative Group
Apr 30, 2005·Stroke; a Journal of Cerebral Circulation·Jonathan BirnsLalit Kalra
Jul 22, 2005·Lancet Neurology·Chengxuan QiuLaura Fratiglioni
May 11, 2006·Journal of Hypertension·Hisatomi ArimaUNKNOWN PROGRESS Collaborative Group
Mar 26, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Ryozo NagaiUNKNOWN JCADII Investigators
Aug 30, 2008·The New England Journal of Medicine·Salim YusufUNKNOWN PRoFESS Study Group
Apr 11, 2009·Stroke; a Journal of Cerebral Circulation·Toshiharu NinomiyaUNKNOWN PROGRESS Collaborative Group
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Oct 3, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Lisheng LiuJiguang Wang
Oct 22, 2009·International Archives of Medicine·Shaheen E Lakhan, Michael T Sapko
Jan 2, 2010·Stroke; a Journal of Cerebral Circulation·Hisatomi ArimaUNKNOWN PROGRESS Collaborative Group
Mar 5, 2011·International Journal of Stroke : Official Journal of the International Stroke Society·Oscar R BenaventeUNKNOWN SPS3 Investigators
Apr 2, 2011·Stroke; a Journal of Cerebral Circulation·Keerthi M MohanAndrew P Grieve
Apr 21, 2012·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Carole L WhiteUNKNOWN SPS3 Investigators
Dec 7, 2013·Stroke; a Journal of Cerebral Circulation·Daniel T LacklandUNKNOWN Council on Functional Genomics and Translational Biology
Jul 30, 2014·Journal of the American Society of Hypertension : JASH·Carlos A Feldstein
Jan 1, 1993·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·UNKNOWN Ticlopidine Aspirin Stroke Study Group

❮ Previous
Next ❯

Citations

Oct 11, 2019·Acta Neurologica Scandinavica·Tomoyuki Kawada
Mar 24, 2020·American Journal of Hypertension·Olivia de MontgolfierEric Thorin
May 20, 2020·JAMA : the Journal of the American Medical Association·Diarmaid HughesMichelle Canavan
Jul 31, 2019·European Cardiology·Mauricio Wajngarten, Gisele Sampaio Silva
Jul 30, 2019·Frontiers in Cardiovascular Medicine·Meghna P MansukhaniVirend K Somers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.